Lentinan potentiates immunity and prolongs the survival time of some patients
Matsuoka, H.; Seo, Y.; Wakasugi, H.; Saito, T.; Tomoda, H.
Anticancer Research 17(4a): 2751-2755
1997
ISSN/ISBN: 0250-7005 PMID: 9252710 Document Number: 483084
For the selection of patients responding well to lentinan, we performed two immunological analysis of patients. Flow cytometric analysis was obtained from peripheral blood lymphocytes; the patients who had greater than 25 ratio of (CD11(-) CD8(+)/CD11(+) CD8(+) after treatment)/(CD11 (-) CD8(+)/CD11 (+) CD8(+) before treatment) at 10 days after lentinan administration showed prolonged survival. The analysis of the levels of soluble factors such as IL-6, sIL6R, TNF-alpha, G-CSF, sICAM-1, IAP, and PGE-2, and the decreasing levels of G-CSF, IL-6, and PGE-2 after lentinan administration had a statistically significant correlation with the ratio of (CD4(+) CD29(+)/CD4(+) CD29(-) after treatment)/((CD4(+) CD29(+)/CD4(+)CD29(-) before treatment). The decrease in IL-6, G-CSF, and PGE-2 levels after lentinan administration indicated an increase in immune potential. From these results, we believe that patients with over 2.5-fold increase in (CD11(-) CD8(+) / CD11(+) CD8(+) after treatment)/(CD11(-) CD8(+) CD11(+) CD8(+) before treatment) and showing a decrease in IL-6, G-CSF, and PGE-2 levels after lentinan administration should continue treatment with lentinan for a long period.